Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Shares Outstanding (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Shares Outstanding for 11 consecutive years, with $16.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 86.85% to $16.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.7 million, a 86.85% increase, with the full-year FY2024 number at $10.7 million, up 20.44% from a year prior.
  • Shares Outstanding was $16.7 million for Q3 2025 at Marker Therapeutics, up from $11.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $83.5 million in Q1 2022 to a low of $8.3 million in Q4 2021.
  • A 5-year average of $25.2 million and a median of $8.9 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: crashed 89.95% in 2022, then skyrocketed 86.85% in 2025.
  • Marker Therapeutics' Shares Outstanding stood at $8.3 million in 2021, then rose by 1.18% to $8.4 million in 2022, then rose by 5.78% to $8.9 million in 2023, then increased by 20.44% to $10.7 million in 2024, then skyrocketed by 55.69% to $16.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Shares Outstanding are $16.7 million (Q3 2025), $11.3 million (Q2 2025), and $11.2 million (Q1 2025).